Combined regimen of temozolomide and liposomal pegylated doxorubicin in glioblastoma - Toxicity and efficacy

被引：0
|
作者：
Hau, P
Jauch, T
Steinbrecher, A
Bogdahn, U
机构：
来源：
NEUROLOGY | 2006年 / 66卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A336 / A336
页数：1
相关论文
共 50 条
  • [1] Combined regimen of temozolomide and liposomal pegylated doxorubicin in glioblastoma:: Toxicity and efficacy -: An update
    Beier, D.
    Hau, P.
    Jauch, T.
    Beier, C.
    Gänbbauer, S.
    Glas, M.
    Koch, H.
    Wismeth, C.
    Steinbrecher, A.
    Bogdahn, U.
    [J]. NEURO-ONCOLOGY, 2006, 8 (04) : 347 - 348
  • [2] TEMOZOLOMIDE/PEGYLATED LIPOSOMAL DOXORUBICIN IN PROGRESSIVE GLIOBLASTOMA MULTIFORME
    Dresemann, Gregor
    [J]. NEURO-ONCOLOGY, 2008, 10 (05) : 826 - 827
  • [3] Temozolomide/pegylated liposomal doxorubicin (PLD) in progressive glioblastoma multiforme (GBM)
    Dresemann, G
    [J]. NEURO-ONCOLOGY, 2005, 7 (03) : 310 - 310
  • [4] Pegylated liposomal doxorubicin: Tolerability and toxicity
    Goram, AL
    Richmond, PL
    [J]. PHARMACOTHERAPY, 2001, 21 (06): : 751 - 763
  • [5] Phase II trial of combined temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy
    Ananda, S.
    Nowak, A. K.
    Cher, L.
    Dowling, A. J.
    Brown, C.
    Simes, R. J.
    Rosenthal, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia
    Yao, Han
    Zhang, Cheng
    Tan, Xu
    Li, Jieping
    Yin, Xiaolin
    Deng, Xiaojuan
    Chen, Ting
    Rao, Jun
    Gao, Lei
    Kong, Peiyan
    Zhang, Xi
    [J]. CANCER MEDICINE, 2023, 12 (11): : 12377 - 12387
  • [7] Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
    Ghaferi, Mohsen
    Raza, Aun
    Koohi, Maedeh
    Zahra, Warda
    Akbarzadeh, Azim
    Shahmabadi, Hasan Ebrahimi
    Alavi, Seyed Ebrahim
    [J]. PHARMACEUTICS, 2022, 14 (10)
  • [8] Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (CaelyxA®)
    Boers-Sonderen, Marye J.
    van Herpen, Carla M. L.
    van der Graaf, Winette T. A.
    Desar, Ingrid M. E.
    Arens-van der Logt, Mirjam G. W.
    de Beer, Yvo M.
    Ottevanger, Petronella B.
    van Erp, Nielka P.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 457 - 463
  • [9] Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)
    Marye J. Boers-Sonderen
    Carla M. L. van Herpen
    Winette T. A. van der Graaf
    Ingrid M. E. Desar
    Mirjam G. W. Arens- van der Logt
    Yvo M. de Beer
    Petronella B. Ottevanger
    Nielka P. van Erp
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 74 : 457 - 463
  • [10] Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer
    Christine Mayer
    Janina Brucker
    Florian Schuetz
    Christoph Domschke
    Sarah Bechstein
    Jörg Heil
    Michael Golatta
    Markus Wallwiener
    Christof Sohn
    Andreas Schneeweiss
    Joachim Rom
    [J]. Archives of Gynecology and Obstetrics, 2016, 294 : 123 - 129
12345